Enteral nutrition in critically ill patients under vasoactive drug therapy: the NUTRIVAD study

Abstract

Background: Enteral nutrition (EN) in critically ill patients requiring vasoactive drug (VAD) support is controversial. This study assesses the tolerability and safety of EN in such patients. Methods: This prospective observational study was conducted in 23 intensive care units (ICUs) over 30 months. Inclusion criteria were a need for VADs and/or mechanic circulatory support (MCS) over a minimum of 48 h, a need for ≥48 h of mechanical ventilation, an estimated life expectancy >72 h, and ≥72 h of ICU stay. Patients with refractory shock were excluded. EN was performed according to established protocols during which descriptive, daily hemodynamic and efficacy, and safety data were collected. An independent research group conducted the statistical analysis. Results: Of 200 patients included, 30 (15%) required MCS and 145 (73%) met early multiorgan dysfunction criteria. Mortality was 24%. Patients needed a mean dose of norepinephrine in the first 48 h of 0.71 mcg/kg/min (95% CI, 0.63–0.8) targeting a mean arterial pressure of 68 mm Hg (95% CI, 67–70) during the first 48 h. EN was started 34 h (95% CI, 31–37) after ICU admission. Mean energy and protein delivered by EN/patient/day were 1159 kcal (95% CI, 1098–1220) and 55.6 g (95% CI, 52.4–58.7), respectively. Daily energy balance during EN/patient/day was −432 (95% CI, −496 to −368). One hundred and fifty‐four (77%) patients experienced EN‐related complications. However, severe complications, such as mesenteric ischemia, were recorded in only one (0.5%) patient. Conclusion: EN in these patients seems feasible, safe, and unrelated to serious complications. Reaching the energy target only through EN is difficult.